Precigen, Inc. · NASDAQ:PGEN
Precigen — Intrexon — Corporate Update (November 2019)
14 slides from Precigen's corporate update, Nov 12, 2019
Slide 1: Precigen Business & Pipeline Update
Precigen Business & Pipeline Update 12 November 2019 Exhibit 99.1
Slide 2: Forward-looking statements
Forward-looking statements Precigen, Inc. is a subsidiary of Intrexon Corporation (Nasdaq: XON). Some of the statements made in this presentation are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking
Slide 3: Dr. Helen Sabzevari, President of Precigen
Dr. Helen Sabzevari President of Precigen
Slide 4: Precigen's technology platforms
CONTROL gene expression and regulation to drive safety CONSTRUCT powerful gene programs to drive efficacy DELIVER gene programs via viral and non-viral based approaches to drive lower costs Precigen’s technology platforms UltraVector® mbIL15 Sleeping Beauty system AttSiteTM recombinases AdenoVerseTM
Slide 5: Precigen's pipeline offers rapid value creation and potential for novel combinations
Precigen’s pipeline offers rapid value creation and potential for novel combinations Precigen pipeline as of November 2019
Slide 6: Disrupting the market: Precigen's transformative UltraCAR-T platform
Disrupting the market: Precigen’s transformative UltraCAR-T™ platform Reliance on viral vectors Complexity of manufacturing viral vectors Long and complex CAR-T cell manufacturing process Long delays for patients High cost of manufacturing Exhausted T cell phenotype Major challenges in solid tumor t
Slide 7: PRGN-3005 UltraCAR-T, a first-in-class therapy in ovarian cancer
PRGN-3005 UltraCAR-T™, a first-in-class therapy in ovarian cancer Advanced non-viral Sleeping Beauty system to co-express CAR, mbIL15 and kill switch Advanced stage platinum resistant ovarian cancer 300k diagnosed annually1/22k in US2 Stage IV survival as low as 20%3 Mucin 16 (MUC16) protein Overexp
Slide 8: PRGN-3005 UltraCAR-T: Phase 1 trial is enrolling patients
PRGN-3005 UltraCAR-T: Phase 1 trial is enrolling patients Clinical trial in collaboration with Uni. of WA & Fred Hutchinson Cancer Center Dose escalation study to determine safety and MTD Arm A: IP infusion Arm B: IV infusion 3x3 dose escalation for IP and IV infusion arms First cohort (dose level 1
Slide 9: PRGN-3006 UltraCAR-T, a first-in-class therapy in AML
PRGN-3006 UltraCAR-T™, a first-in-class therapy in AML Relapsed or refractory acute myeloid leukemia (AML) 20k diagnosed in US in 20181 Higher risk myelodysplastic syndrome (MDS) US incidence >10k per year2 Patient Population Advanced non-viral Sleeping Beauty system to co-express CAR, mbIL15 and ki
Slide 10: PRGN-3006 UltraCAR-T: Phase 1/1b trial is enrolling patients
PRGN-3006 UltraCAR-T: Phase 1/1b trial is enrolling patients Dose escalation study to determine safety and MTD Arm 1: NO lymphodepletion Arm 2: With lymphodepletion 3x3 dose escalation design followed by dose expansion phase at MTD for each arm Study in collaboration with Moffitt Cancer Center First
Slide 11: PRGN-2009 AdenoVerse immunotherapy showed anti-tumor activity in HPV+ head & neck cancer mouse model
PRGN-2009 off-the-shelf AdenoVerse™ immunotherapy showed robust anti-tumor activity in humanized mouse model of HPV+ head & neck cancer CD8+ T cells / mg tumor Increase in CD8+ T cell infiltration in tumor after PRGN-2009 treatment in mice PRGN-2009 immunotherapy effectively controls HPV+ head & nec
Slide 12: Multifunctional therapeutics overcome tumor microenvironment immunosuppression
Multifunctional therapeutics overcome tumor microenvironment immunosuppression and improve T cell function compared to anti-PD1 in preclinical mouse models PRGN-5001 exhibits superior anti-tumor effect compared to anti-PD1 in humanized mouse model of Head and Neck cancer PRGN-5002 exhibits superior
Slide 13: Portfolio Advancement in 2019
Portfolio Advancement in 2019 Rapidly advance preclinical and clinical programs þ þ þ þ þ Initiate PRGN-3006 UltraCAR-T TM Phase 1 trial in AML and MDS Rapidly advance PRGN-3005 UltraCAR-T TM for solid tumor Rapidly advance PRGN-2009 AdenoVerse TM immunotherapy for solid tumor Rapidly advance one in
Slide 14: EUG
EUG in t r e x on Pp ADY < )VANCI E ING C C IGS!